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Abstract
Background: Lesions in the avascular two-thirds
of the meniscus do not heal well and are of concern
clinically. Various growth factors promote the syn-
thesis of matrix by meniscal cells and thus have the
potential to augment healing. However, their clinical
application is severely hindered by problems with
delivery. An attractive approach to overcoming such
problems is to transfer genes that encode the growth
factors in question to the site of the injury. As a prelude
to this, we evaluated methods for delivering genes to
the meniscus.
Methods: Gene transfer was evaluated in vitro and
in vivo with a lacZ marker gene, which expresses the
enzyme b-galactosidase. Two types of vectors were
tested: an adenovirus and a retrovirus. Monolayers of
lapine, canine, and human meniscal cells, as well as
intact lapine and human menisci, were used for the in
vitro studies. Lesions were created in the menisci of
rabbits and dogs for the in vivo studies. Gene transfer
to the sites of the experimental meniscal lesions in
vivo was accomplished in two ways. In the lapine
model, a suspension of adenovirus carrying the lacZ
marker gene was mixed with whole blood and the clot
was inserted into the lesion. In the canine model, retro-
virally transduced allogenic meniscal cells carrying the
lacZ marker gene were embedded in collagen gels and
transferred to the defects. The animals were killed at
various time-points, and gene expression was evaluated
by histological examination of sections stained with
5-bromo-4-chloro-indolyl-b-D-galactose (X-gal), from
which a blue chromagen is released in the presence of
b-galactosidase.
Results: Monolayer cultures of lapine, canine, and
human meniscal cells were susceptible to genetic trans-
duction by both adenoviral and retroviral vectors.
In vitro gene transfer to intact human and lapine me-
nisci proved possible both by direct, adenoviral, deliv-
ery and indirect, retroviral, delivery. Gene expression
persisted for at least twenty weeks under in vitro con-
ditions. With regard to the in vivo studies, gene ex-
pression persisted within the clot and in some of the
adjacent meniscal cells for at least three weeks in the
lapine defect model. In the canine defect model, gene
expression persisted within the transplanted, trans-
duced meniscal cells for at least six weeks.
Conclusions: It is possible to transfer genes to sites
of meniscal damage and to express them locally within
the lesion for several weeks.
Clinical Relevance: Healing of the avascular portion
of the meniscus may be improved by the transfer of
genes encoding the appropriate growth factors. To our
knowledge, the present report is the first to describe
methods for transferring genes to the meniscus. When
used in conjunction with the appropriate growth-factor
genes, these techniques should help to provide the ba-
sis for potential alternative treatment options for menis-
cal lesions. Additional studies are needed to determine
whether these techniques will lead to improved healing
of meniscal defects in vivo.
The menisci serve many important biomechanical
functions, including load-bearing, shock absorption, and
load transmission. They also contribute to the stability
of the knee14. Because of a greater understanding of
the importance of the menisci and many reports dem-
onstrating an early onset of degenerative changes in
the knee joint following meniscectomy4,6,20, orthopaedic
surgeons now aim to preserve as much functional menis-
cal tissue as possible when treating meniscal injuries.
Because the periphery of the meniscus receives a
rich blood supply, tears in this location are reparable.
In contrast, the inner two-thirds of the meniscus is rel-
atively avascular. The results of meniscal repair in this
zone are variable, although many techniques have been
developed in attempts to promote healing in this re-
gion2,7,15,24. One approach is to use growth factors, which
accelerate the healing process12. It has been demon-
strated that meniscal fibrochondrocytes are capable of
enhanced proliferation and matrix synthesis when ex-
posed to growth factors that are normally present in
wound hematomas3,13,19,21,22. Moreover, animal studies
have shown that the addition of growth factors dur-
ing conventional methods of meniscal repair improves
healing9.
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For this approach to be successful, a method is
needed with which to deliver the growth factors locally
to the lesion and to maintain the sustained release
of the growth factors over time. Direct application of
growth factors by themselves is not likely to be successful
because of their short biological half-lives. The implanta-
tion of bioresorbable slow-release devices, while possi-
ble, has yet to be realized in a clinically useful manner.
Gene transfer provides a promising alternative strat-
egy5. Delivery to the meniscus of a gene encoding the
growth factor of interest may make it possible to achieve
sustained local endogenous synthesis of the growth fac-
tor at the site of healing. There are many advantages
to this approach, including the potential for regulating
both the level and the duration of growth-factor pro-
duction5. Endogenous synthesis also ensures that, unlike
recombinant growth factors produced by prokaryotic
cells, the growth factor has undergone appropriate
posttranslation modification. The present study was de-
signed to evaluate the feasibility of gene transfer to the
meniscus.
There are two main strategies for transferring genes
to sites in the body5. With in vivo, or direct, gene delivery,
the new genetic material is introduced directly into the
patient. With ex vivo, or indirect, gene delivery, cells are
removed, genetically manipulated outside the body, and
then returned to the body. The cells used in ex vivo gene
delivery do not necessarily have to be derived from the
target organ.
Gene delivery is facilitated by the use of vectors,
which enable the cellular uptake and expression of the
transferred genes. A variety of viral and nonviral vectors
are available for this purpose17. In the present study, we
elected to evaluate vectors developed from an adeno-
virus and a retrovirus. Adenoviruses infect both divid-
ing and nondividing cells very efficiently and may be
used for both in vivo and ex vivo gene delivery. In con-
trast, retroviruses only transduce dividing cells and are
predominantly used in ex vivo protocols. In both cases,
the viruses in the present study were used to trans-
fer a bacterial marker gene, lacZ, which expresses the
enzyme β-galactosidase. Cells expressing this enzyme,
which is not normally found in mammalian cells, can be
stained blue by a simple histochemical procedure.
Materials and Methods
Viral Vectors
Two types of viral vectors were used in this study: adenovirus
and retrovirus. The E1 and E3 regions of the genome were deleted in
the adenoviral vector. The marker gene used in this study, lacZ, was
cloned into the E1 region under the control of a human cytomegalo-
virus early promoter. The virus was prepared with standard methods,
which yielded a suspension containing 109 plaque-forming units per
milliliter.
The retroviral vector was based on the Moloney murine leukemia
virus. It contained the lacZ gene under the control of the retroviral 5′
long terminal repeat and the neomycin phosphotransferase gene un-
der the control of the simian virus 40 early promoter16. The latter gene
renders cells resistant to the neomycin analog G418. This virus was
generated at titers of approximately 105 infectious viral particles per
milliliter from a producer line known as CRIP.
Meniscal Cell Culture
Menisci were retrieved from the knee joints of three-month-old
New Zealand White rabbits that weighed approximately 2.5 kilo-
grams, adult mongrel dogs that weighed twenty-five to thirty kilo-
grams, and three patients who were fourteen, sixteen, and twenty-eight
years old and had a medial meniscal tear. The removal of human
menisci was approved by the local institutional review board. Cells
were isolated from the menisci with the method described by Green8.
Briefly, the menisci were cut into approximately three-millimeter-long
pieces. The cells were released from the meniscal fragments by sequen-
tial digestion with 0.2 percent (weight per volume) trypsin for thirty
minutes and 0.2 percent (weight per volume) collagenase for three
hours at 37 degrees Celsius and were then seeded into twenty-five-
square-centimeter tissue-culture flasks (T-25 tissue culture flask; VWR
Scientific, Bridgeport, New Jersey) that contained four milliliters of
Ham’s F-12 medium (Gibco, Grand Island, New York) supplemented
with 10 percent fetal bovine serum (Gibco), and 1 percent penicillin
and streptomycin (weight per volume) (Gibco).
Cell Transduction in Vitro
Adenoviral transduction: When the cells were confluent, the me-
dium was removed, and the cell monolayer was washed twice with
four milliliters of Gey’s balanced salt solution (Gibco). One milliliter
of adenoviral vector suspension was added to give a ratio of 108 viral
particles per million cells. The cells were incubated for three hours,
with gentle shaking every thirty minutes. After the three hours of
incubation, three milliliters of fresh medium was added and the cells
were returned to the incubator.
Retroviral transduction: Confluent cultures were trypsinized and
subcultured at a 1:3 split ratio. When the first-passage cultures were
60 percent confluent, the medium was removed, the cells were washed
with Gey’s balanced salt solution as described, and one milliliter of
retroviral vector suspension was added in the presence of eight mi-
crograms of polybrene (Sigma Chemical, St. Louis, Missouri) per mil-
liliter. This provided a ratio of 5 × 106 viral particles per million
cells. The cells were incubated for three hours, with gentle shaking
every thirty minutes. After the three hours of incubation, three mil-
liliters of fresh medium was added and the cells were returned to
the incubator. When the cells were confluent, they were trypsinized
and replated and 0.25 milligram of G418 (Sigma) per milliliter was
added into the culture medium to select for transduced cells11. Cells
that expressed the neomycin phosphotransferase gene contained
in the retrovirus were resistant to the cytotoxic actions of G148. To
detect lacZ gene expression by the transduced cells, the cultures
were histochemically stained blue with the chromogenic substrate 5-
bromo-4-chloro-indolyl-β-D-galactose (X-gal; Sigma), as described
previously16, at every passage. The percentage of lacZ+ cells was de-
termined by scoring cells as positive (blue) or negative (colorless)
histologically. At least 100 cells were scored in each case.
In Vitro Gene Transfer to Menisci 
Whole lapine menisci (four, five, or six per dish) and human
meniscal fragments (two to five millimeters; eight, nine, or ten per
dish) were placed in sixty-millimeter Petri dishes that contained five
milliliters of the culture medium described earlier.
For direct gene delivery, 0.1 milliliter of the adenoviral vector
suspension was injected into the menisci or meniscal fragments at
four locations with use of a one-milliliter syringe and a 25-gauge
needle. Four menisci or meniscal fragments were injected at each
time-point (at one, two, eight, twelve, sixteen, and twenty weeks after
the gene transfer).
For indirect gene delivery to the menisci or meniscal fragments,
cultured meniscal cells were transduced with the retrovirus containing
the lacZ and neomycin phosphotransferase genes and were selected
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in G418 as described earlier. Monolayer cultures of cells were then
trypsinized and centrifuged at 2000 revolutions per minute for ten
minutes. The cells were collected and were suspended in 0.5 milliliter
of Ham’s F-12 medium with 10 percent fetal bovine serum and 1
percent penicillin and streptomycin to a final concentration of 106 cells
per milliliter. One hundred microliters (105 cells) of the cell suspension
was injected at multiple locations into the procured meniscal tissue
with a one-milliliter syringe and a 25-gauge needle.
After the injections, the intact lapine and fragmented human
menisci were placed in Petri dishes that contained the culture me-
dium that lacked G418, and they were maintained in the incubator.
The meniscal tissues were fixed sequentially, at one, two, four, eight,
twelve, sixteen, and twenty weeks after the gene transfer, with 0.01-
molar phosphate-buffered saline solution (Sigma) containing 4 per-
cent paraformaldehyde (Fisher Scientific, Fair Lawn, New Jersey). The
meniscal tissue was stained with X-gal to detect gene expression by
the transduced cells. The stained menisci were then cut along the
transverse plane through the site of the injection. Tissue specimens
were dehydrated and embedded in paraffin wax. Paraffin sections
were cut at a thickness of five micrometers and were affixed to glass
slides. Deparaffinized and hydrated sections were stained with eosin
as a counterstain for X-gal.
In Vivo Gene Transfer to Operatively
Created Meniscal Lesions
Adenovirally Mediated ex Vivo Gene
Transfer to Lapine Meniscal Lesions
Six New Zealand White rabbits, which weighed approximately 2.5
kilograms, were given anesthesia. Arthrotomies were performed on
both knees under sterile conditions, and the medial menisci were
exposed. A two-millimeter-long incision was made in the avascular
area of the anterior part of the medial meniscus. A fibrin clot that had
formed after 0.5 milliliter of whole blood was mixed with 0.3 milliliter
of adenoviral suspension was transplanted into the incised meniscal
lesion. A fibrin clot that did not have the viral vector was transplanted
into the lesion in the contralateral knee to serve as a control. After
the clot had been inserted, the capsule was closed carefully and the
skin was closed with a subcuticular stitch. The animals were mobilized
postoperatively and were given a standard diet. Two rabbits each were
killed at one, two, and three weeks after the operation. The menisci
were obtained, fixed with 0.01-molar phosphate-buffered saline solu-
tion that contained 4 percent paraformaldehyde, and stained with
X-gal. The stained menisci were cut along the transverse plane through
the tear and were embedded, sectioned, and stained as described.
Retrovirally Mediated ex Vivo Gene
Transfer to Canine Meniscal Lesions
Canine meniscal cells were transduced with retrovirus that con-
tained the lacZ and neomycin phosphotransferase genes and were
selected in G418. Staining with X-gal before implantation into a de-
fect demonstrated that nearly 100 percent of the cells were trans-
duced. After confluence, they were trypsinized and centrifuged at 2000
revolutions per minute for ten minutes. The cell pellet was incor-
porated in a collagen gel suspension. To accomplish this, eight vol-
umes of purified type-I collagen solution (Vitrogen 100; Celtrix, Santa
Clara, California), one volume of ten-times-concentrated phosphate-
buffered saline solution, and one volume of 0.1-molar sodium hydrox-
ide were added, with gentle agitation, at 4 degrees Celsius, and the pH
of the solution was adjusted to 7.2 ± 0.2. Finally, one volume of cell
suspension was added to the neutralized, isotonic collagen mixture
and was incubated in a culture dish at 37 degrees Celsius for twenty-
four hours to gel the collagen (final concentration, 1.8 × 106 cells per
milliliter; 0.21 percent collagen)10,23.
TABLE I
LACZ EXPRESSION BY MENISCAL CELLS
AFTER RETROVIRAL TRANSDUCTION IN VITRO








 48 hrs., unselected 20 18 10
 1 wk., selected in G418 95 98 93
 2 wks., selected in G418 98 95 98
 4 wks., selected in G418 90 93 95
 28 wks., selected in G418 93 98 92
*The time-periods refer to the interval after transduction.
Horizontal section of a human meniscus two weeks after an adenoviral vector containing the lacZ gene was injected directly into the
meniscus in vitro (X-gal and eosin, × 200). High levels of gene expression are evident (blue areas).
FIG. 1
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Twelve adult mongrel dogs that weighed twenty-five to thirty
kilograms were used. All of the dogs had a normal gait and a full
range of motion of the limbs. General anesthesia was given and endo-
tracheal intubation was used. Inhalation anesthesia was maintained
with a mixture of isoflurane, nitrous oxide, and oxygen. The hindlimbs
were shaved, prepared with iodine, and draped in a sterile fashion.
A medial parapatellar skin incision was made through the subcuta-
neous tissue down to the joint capsule. The capsule was dissected to
expose the medial collateral ligament. This ligament was detached at
the femoral insertion and was reflected distally to expose the me-
dial meniscus. A partial-thickness circular defect, two millimeters in
diameter and three millimeters deep, was made three millimeters
from the meniscosynovial junction in the middle third of the menis-
cus. The collagen gel with the transduced canine cells was implanted
into the defect. A collagen gel without cells was implanted in the
contralateral meniscus to serve as a control. After transplantation,
the medial collateral ligament was reattached at the site of its original
insertion with interosseous sutures. The capsule was closed carefully,
and the skin was closed with a subcuticular stitch. The animals were
mobilized postoperatively, given a standard diet, and allowed to walk
outside the cages at one week after the operation. LacZ gene expres-
sion in the menisci was evaluated at one, two, four, and six weeks
postoperatively. Three animals were killed at each time-period. The
menisci were obtained, fixed with 0.01-molar phosphate-buffered sa-
line solution that contained 4 percent paraformaldehyde, and stained
with X-gal. The stained menisci were cut along the radial plane
through the defect and were embedded, sectioned, and stained as
described earlier.
Results
Our studies of transfer of the lacZ marker gene to
the meniscus comprised three parts: in vitro transduc-
tion of cultured cells with adenoviral and retroviral vec-
tors, direct and indirect in vitro delivery of the lacZ
marker gene with adenovirus and retrovirus to procured
menisci, and ex vivo delivery of the lacZ marker gene
with adenovirus and retrovirus to operatively created
meniscal lesions in the knee joints of rabbits and dogs.
In Vitro Gene Transfer to Monolayer Cultures
The tranduction of lapine, canine, and human menis-
cal cells was first accomplished with a retrovirus capable
of expressing the lacZ and neomycin phosphotransfer-
ase genes simultaneously.
After the lapine, canine, and human meniscal cells
were transduced with this retrovirus, expression of the
lacZ gene was seen initially in 20, 18, and 10 percent
of cells, respectively (Table I). Selection of transduced
cells in G418 increased the percentage of transduced
cells to nearly 100 (Table I). Transgene expression after
transduction with the retrovirus and selection in G418
was stable and lasted twenty-eight weeks in vitro, at
which time the experiment was terminated. During this
twenty-eight-week period, the cells were taken through
approximately fifteen passages, without reduction in the
percentage of cells expressing lacZ. These experiments
were repeated five times with the same results.
Lapine, canine, and human meniscal cells were also
transduced with an adenovirus carrying the lacZ gene.
At a multiplicity of infection of fifty, nearly 100 percent
of the cells of each species expressed the lacZ gene after
TABLE II
LACZ EXPRESSION BY MENISCAL CELLS
AFTER ADENOVIRAL TRANSDUCTION IN VITRO








  48 hrs. 90 95 95
  4 wks., passaged 12 15 18
  20 wks., unpassaged 90 88 85
*The time-periods refer to the interval after transduction.
Horizontal section of a lapine meniscus three weeks after an adenoviral vector containing the lacZ gene was incorporated into a fibrin clot
and then implanted into a meniscal tear (X-gal and eosin, × 200). Cells within the fibrin clot have expressed the transgene (blue areas).
FIG. 2
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transduction with this virus (Table II). Gene expression
after adenoviral transduction was stable for all species
for twenty weeks in confluent, nondividing cultures, but,
unlike expression after retroviral transduction, it was
not stable on passage (Table II).
In Vitro Gene Transfer to Menisci
Direct Gene Transfer
Direct retroviral transfer was not attempted because
retroviral vectors only transduce dividing cells.
Whole lapine menisci and fragments of human me-
nisci were used to assess the feasibility of direct viral
gene transfer with the adenoviral vector carrying the
lacZ gene. In vitro injection of this vector directly into
lapine menisci led to the transduction of cells adjacent
to the track of the needle but not elsewhere, suggesting
that the dense, meniscal matrix impeded diffusion of
the virus. Human meniscal cells were also transduced
after direct injection of adenoviral vectors (Fig. 1). High
levels of gene expression persisted in both lapine and
human menisci for twenty weeks in vitro, at which time
the experiment was discontinued. In general, injection
of the adenovirus vector carrying the lacZ gene into
human menisci transduced cells within a wider radius
than did injection into lapine menisci.
Indirect Gene Transfer
LacZ gene expression was detected within lapine
and human menisci by X-gal-staining at all time-points
during the twenty weeks after the injection of allogenic
cells transduced with the retrovirus carrying the lacZ
and neomycin phosphotransferase genes.
In Vivo Gene Transfer to Operatively
Created Meniscal Lesions
Ex Vivo Gene Transfer with a Fibrin Clot
Histochemical analysis of retrieved lapine menisci
confirmed that the virus had succeeded in transferring
the lacZ gene to cells within the clot and also to certain
meniscal cells lining the lesion. Expression of the lacZ
gene persisted in these tissues for three weeks (Fig. 2),
at which time the experiment was discontinued.
Ex Vivo Transfer of Transduced
Meniscal Cells in Collagen Gel
Transplanted cells were detected by X-gal-staining
of the tissue in the defect and the meniscosynovial
junction near the defect at one, two, four, and six weeks
Figs. 3-A through 3-E: Radial sections of canine menisci after
retrovirally mediated ex vivo gene transfer to an operatively created
defect (and control specimens) (X-gal and eosin).
Fig. 3-A: Two weeks after gene transfer, there was a large number
of lacZ+ cells (stained blue) in the defect (× 200).
Four weeks after gene transfer, there were lacZ+ cells (stained
blue) embedded in a dense fibrous tissue in the defect (× 400).
FIG. 3-A
FIG. 3-B
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after implantation (Figs. 3-A, 3-B, and 3-C). The cells
detected in the fibrous tissues appeared fibroblastic,
whereas cells that resembled fibrochondrocytes could
be identified in the body of the meniscus (Fig. 3-A).
Transduced allografted cells were detected in lesions six
weeks after the operation (Fig. 3-C). Control defects
in which no cells had been implanted showed no stain-
ing at any time postoperatively (Figs. 3-D and 3-E).
The operatively created defects were filled with fibrous
tissue that contained fibroblastic cells and inflamma-
tory cells.
Discussion
The results of the present study confirm that, al-
though a meniscal defect becomes filled with fibrous
tissue containing fibroblasts by six weeks postopera-
tively, this tissue is histologically different from nor-
mal meniscal tissue. This finding agrees with that of
Arnoczky et al.2, who showed that a similarly sized, full-
thickness defect in a canine meniscus filled with a fibrin
clot was still morphologically different from the adja-
cent meniscal tissue at three months.
Port et al.15 evaluated healing biomechanically af-
ter fibrin clots and cultured autogenous marrow cells
were placed in operatively created, full-thickness me-
niscal lesions in goats. They found no enhancement in
healing at four months. Their results demonstrated that
the fibrin clot, even though it contains chemotactic and
mitogenic factors as well as additional cellular com-
ponents, could not induce complete healing of caprine
meniscal lesions. This finding suggests that a single appli-
cation of the growth factors present in fibrin clots may
not promote healing, a circumstance that could reflect
the necessity for growth factors to be present within the
lesion for an extended period of time. However, with
existing technology, high concentrations of growth fac-
tors cannot be delivered to sites of meniscal damage in
a sustained fashion. In an effort to solve this problem,
two of us (P. D. R. and C. H. E.) are developing gene-
transfer techniques5 that could be used to promote the
sustained, localized production of growth factors within
the meniscal lesion in order to improve healing.
The present study confirms that gene transfer to
meniscal cells is feasible in lapine, canine, and human
menisci. With use of the lacZ gene as a marker, we
showed that both adenovirally and retrovirally mediated
Six weeks after gene transfer, there were lacZ+ cells (stained blue)
in the defect (× 400).
A control specimen in which collagen gel without cells had been
implanted (× 200). Two weeks postoperatively, the defect was filled
with inflammatory cells and fibroblasts in a sparse fibrous tissue. No
background staining was seen after treatment with X-gal, and thus no
lacZ+ cells were present.
FIG. 3-D
FIG. 3-C
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gene transfer can maintain gene expression for at least
twenty weeks in vitro.
Because the in vitro data suggested that ex vivo gene
delivery to a meniscus is more efficient than in vivo
gene delivery, the former strategy was employed for
gene transfer to operatively created meniscal lesions
in experimental animals. Since adenovirus infects non-
dividing cells, it was possible to utilize this vector in
a fibrin-clot technique. The adenoviral vector suspen-
sion and the fibrin clot were mixed before implantation
into the meniscal lesion. Although few meniscal cells
were transduced by this method, cells trapped within the
clot expressed the transgene very efficiently and could
serve as a local source of growth-factor synthesis. In this
sense, the identity of the transduced cells within the
clot is not critical, provided that they transduce and
express the transgene efficiently. An advantage of the
fibrin-clot method is that fibrin clots are already used in
operative meniscal repairs, and thus they lend them-
selves to early use as an adjunct to gene transfer in
humans. Moreover, unlike the method involving use of
retroviruses, this method does not require cell culture.
Adenovirally mediated gene delivery combined with
the fibrin-clot technique was successful for delivery of
the lacZ gene to the meniscal lesion, with gene expres-
sion persisting within the clot for the entire three-week
period of the experiment.
Retroviruses do not transduce nondividing cells,
such as those found in fibrin clots, but they proved to be
effective mediators of gene transfer to meniscal cells
under in vitro conditions in which the cells divide. More-
over, because retroviruses insert their genetic material
stably into the chromosomal DNA of the cells that they
infect, there is no dilution of the transferred genes dur-
ing cell division and it is possible to select for cells
expressing the genes of interest. For ex vivo gene de-
livery with retroviruses, cells were transduced, selected
in G418, and embedded in collagen gels before trans-
plantation and insertion into the meniscal defect. This
technique was efficient not only in preventing the cells
from migrating from the meniscal lesion but also in
maintaining the morphology of the transferred me-
niscal cells. The collagen gel used in this study contained
95 to 98 percent type-I collagen, with the remainder
being type-III collagen. Therefore, this collagen-and-cell
mixture could be a suitable scaffold for maintaining
the integrity of meniscal tissue after transplantation to
the lesion. Transgene expression persisted for six weeks
after allotransplantation of the retrovirally transduced
cells into partial-thickness meniscal defects.
The three to six-week duration of gene expression
in the meniscal defects noted in the present study may
be long enough to enhance healing if a therapeutic
gene is utilized. Meniscal cells are known to respond to
exogenously supplied growth factors3,9,21, and articular
chondrocytes have been shown to respond to transfer of
a transforming-growth-factor gene by increasing matrix
synthesis1,18. This permits cautious optimism regarding
the possibility that these techniques could form the basis
of a gene-transfer approach to the repair of meniscal
lesions.
NOTE: The authors express sincere thanks to Dr. Rebecca K. Studer, Helga I. Georgescu,
Lori Miller, Warren Thompson, Dr. Chang W. Lee, and the Pathology Development Labora-
tory, Presbyterian-University Hospital.
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